VNDA

5.27

0.29% 0.05

Handel nachbörslich: 5.26 -0.010 -0.19%

Vanda Pharmaceuticals Inc (VNDA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$5.22

Offen:

$5.15

24-Stunden-Volumen:

683.83K

Relative Volume:

0.72

Marktkapitalisierung:

$318.64M

Einnahmen:

$217.78M

Nettoeinkommen (Verlust:

$-239.55M

KGV:

-1.3015

EPS:

-4.0492

Netto-Cashflow:

$-127.30M

1W Leistung:

+4.28%

1M Leistung:

-3.77%

6M Leistung:

-15.56%

1J Leistung:

+20.07%

1-Tages-Spanne:

$5.13

$5.335

1-Wochen-Bereich:

$4.849

$5.335

52-Wochen-Spanne:

$4.27

$9.94

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Firmenname

Vanda Pharmaceuticals Inc

Sektor

Healthcare (1089)

Branche

Biotechnology (604)

Telefon

202-734-3400

Adresse

2200 PENNSYLVANIA AVE NW, WASHINGTON

Mitarbeiter

533

Twitter

Nächster Verdiensttermin

2026-07-30

Neueste SEC-Einreichungen

VNDA's Discussions on Twitter

Compare VNDA vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VNDA Vanda Pharmaceuticals Inc	5.27	315.62M	217.78M	-239.55M	-127.30M	-4.0492
VRTX Vertex Pharmaceuticals Inc	515.57	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.86	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	986.80	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.94	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.66	39.31B	5.76B	514.49M	1.10B	4.4813

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-05	Eingeleitet	Truist	Buy
2025-11-05	Eingeleitet	B. Riley Securities	Buy
2024-10-31	Eingeleitet	H.C. Wainwright	Buy
2024-07-11	Eingeleitet	Cantor Fitzgerald	Overweight
2022-02-25	Herabstufung	Jefferies	Buy → Hold
2021-05-12	Eingeleitet	BofA Securities	Buy
2021-01-14	Herabstufung	Citigroup	Buy → Neutral
2020-10-29	Hochstufung	Citigroup	Neutral → Buy
2020-06-09	Herabstufung	Citigroup	Buy → Neutral
2020-03-16	Herabstufung	Oppenheimer	Perform → Underperform
2020-03-12	Hochstufung	Citigroup	Neutral → Buy
2019-11-07	Herabstufung	Citigroup	Buy → Neutral
2019-08-01	Hochstufung	Citigroup	Neutral → Buy
2019-07-25	Herabstufung	Stifel	Buy → Hold
2018-12-11	Herabstufung	Oppenheimer	Outperform → Perform
2018-12-04	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2018-12-04	Bestätigt	Jefferies	Buy
2018-11-08	Fortgesetzt	Jefferies	Buy
2018-09-21	Fortgesetzt	Oppenheimer	Outperform
2018-05-23	Eingeleitet	Citigroup	Buy
2018-01-19	Eingeleitet	Seaport Global Securities	Buy
2017-09-14	Bestätigt	Piper Jaffray	Overweight
2017-06-27	Fortgesetzt	Piper Jaffray	Overweight
2017-05-26	Eingeleitet	H.C. Wainwright	Buy
2017-04-12	Eingeleitet	Oppenheimer	Outperform
2016-11-09	Eingeleitet	Aegis Capital	Buy
2016-10-06	Fortgesetzt	Jefferies	Buy

Alle ansehen

Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten

06:55 AM

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat

06:55 AM

Aug 16, 2026

Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0

Aug 16, 2026

Aug 15, 2026

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits

Aug 15, 2026

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits

Aug 15, 2026

Aug 14, 2026

Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits

Aug 14, 2026

Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us

Aug 14, 2026

Aug 13, 2026

AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan

Aug 13, 2026

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 13, 2026

Aug 12, 2026

Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat

Aug 12, 2026

Aug 11, 2026

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits

Aug 11, 2026

Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits

Aug 11, 2026

Aug 10, 2026

VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus

Aug 10, 2026

Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat

Aug 10, 2026

B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com

Aug 10, 2026

H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com

Aug 10, 2026

H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada

Aug 10, 2026

VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Aug 10, 2026